Latest:
Dr. Fox Discusses Genomic Testing in Breast Cancer
Dr. Kevin Fox, from Abramson Cancer Center, Discusses Genomic Testing in Breast Cancer
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Kevin R. Kelly, MD, PhD
Latest:
Dr. Kelly on BT062 Combination With Lenalidomide for R/R Myeloma
Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses indatuximab ravtansine (BT062) in combination with lenalidomide (Revlimid) in patients with relapsed or refractory multiple myeloma.
Kevin S. Hughes, MD
Latest:
Dr. Hughes on RT in Elderly Patients With ER+ Breast Cancer
Kevin S. Hughes, MD, co-director, Avon Comprehensive Breast Evaluation Center, medical director, Bermuda Cancer Genetics and Risk Assessment Clinic, Harvard Medical School, Massachusetts General Hospital, discusses treatment with radiation therapy for patients with ER-positive breast cancer.
Kevin W. Su, BS
Latest:
Changes in Prostate Cancer Presentation for Radiation Oncology Care
USPSTF guidelines may have decreased the number of patients presenting with prostate
cancer for radiation oncology care, particularly those with low-risk disease, without a
short-term increase in higher-risk disease.
Kevin Wright
Latest:
Pembrolizumab Plus Chemoradiation Therapy Yields Promising Results for Patients with Unresectable, Locally Advanced NSCLC
January 29, 2021 - The combination of pembrolizumab plus concurrent chemoradiation therapy showed antitumor activity in patients with unresectable, locally advanced, stage III non–small cell lung cancer, regardless of PD-L1 status or tumor histology.
Khaled A. Hassan, MD, MS
Latest:
Dr Hassan on the CHRYSALIS trial of Amivantamab in EGFR Exon 20–Mutated NSCLC
Khaled Hassan, MD, discusses key results from the phase 1 CHRYSALIS trial of the bispecific antibody amivantamab-vmjw in non–small cell lung cancer expressing EGFR exon 20 insertion mutations.
Kilian Salerno, MD
Latest:
Dr. Salerno Discusses Hypofractionation for Early Breast Cancer
Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer.
Kim N. Chi, MD
Latest:
Dr. Chi on the TITAN Trial Results in Metastatic Castration-Sensitive Prostate Cancer
Kim N. Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the results of the phase III TITAN trial, which evaluated apalutamide versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).